Ryann Sohaney, DO
Internal Medicine · Ann Arbor, MINPI 1790103042
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,237 of the $1,648 with a category attached, or 75.0%. AstraZeneca accounts for 64.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $1,066 and has fallen 56.5% since, to $463 in 2025.
Across 11 payments — averaging $149.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$463
- Vifor Pharma, Inc.$118
Across 8 payments — averaging $20,662 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$116K
- Novartis$48K
- Vertex$1K
What the payments were for
- Travel & lodging$1,23775%
- Food & beverage$41125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $1,066 |
| Novartis | 1 | $463 |
| Vifor Pharma, Inc. | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$118
How this compares
$1,648 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $44,068 |
| Sevelamer Carbonate | 33 | $8,007 |
| Nifedipine ErNifedipine | 90 | $4,369 |
| Calcium Acetate | 38 | $2,526 |
| Labetalol Hcl | 24 | $1,086 |
| Losartan Potassium | 95 | $1,069 |
| Amlodipine Besylate | 57 | $549 |
| Carvedilol | 52 | $499 |
| Atorvastatin Calcium | 39 | $490 |
| Bumetanide | 16 | $468 |
| Torsemide | 23 | $448 |
| Lisinopril | 41 | $441 |
| Felodipine ErFelodipine | 13 | $429 |
| Metoprolol Succinate | 20 | $422 |
| Spironolactone | 16 | $323 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Ann Arbor
- Terry SmithAnn Arbor$2.3M
- Ulka VaishampayanAnn Arbor$996K
- A FendrickAnn Arbor$347K
- Gazala KhanAnn Arbor$86K
- Michael ValituttoKalamazoo$1.8M
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.